Premium
Antidepressant with novel mechanism of action shows promise in Phase 2 trial
Publication year - 2020
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30516
Subject(s) - antidepressant , placebo , mechanism of action , allosteric modulator , pharmacology , allosteric regulation , medicine , depression (economics) , neuroactive steroid , mechanism (biology) , depressive symptoms , clinical trial , psychiatry , neuroscience , receptor , psychology , alternative medicine , anxiety , biology , gabaa receptor , biochemistry , in vitro , philosophy , macroeconomics , epistemology , pathology , economics
Daily oral administration of SAGE‐217, a synthetic neurosteroid and positive allosteric GABA A receptor modulator, reduced depressive symptoms relative to placebo in a Phase 2 study involving 89 patients with major depression. The promising results were seen both among patients taking and not taking an antidepressant, researchers reported. Study results were published Sept. 5 in the New England Journal of Medicine .